Stroke Treatment Academic Industry Roundtable (STAIR) Recommendations for Maximizing the Use of Intravenous Thrombolytics and Expanding Treatment Options With Intra-arterial and Neuroprotective Therapies

Background and Purpose— The goal of the Stroke Treatment Academic Industry Roundtable (STAIR) meetings is to advance the development of acute and restorative stroke therapies. Summary of Review— At the STAIR VII recommendations for strategies to maximize the use of intravenous thrombolytics through targeting public education, and the refinement of current treatment exclusion criteria were proposed. Increased utilization of mechanical devices for intra-arterial recanalization can be achieved by obtaining more definitive evidence of efficacy in randomized clinical trials, identification of patient characteristics associated with treatment efficacy, optimization of technical approaches, clarification of effective time windows, and development of approaches to limit complications. Neuroprotective strategies remain viable; recommendations for further study of these agents include an emphasis on rapid administration, consideration of the systemic effects of ischemic stroke, prevention of complications associated with early reperfusion, a focus on agents with multiple mechanisms of action, and consideration of possible interactions between neuroprotective and thrombolytic therapies. Conclusions— Extending intravenous thrombolysis to a broader patient population, clarifying the risk and benefits of intra-arterial reperfusion therapies, and further development of neuroprotective therapies were the key recommendations from STAIR VII.

[1]  P. Davis,et al.  Cooling for newborns with hypoxic ischaemic encephalopathy. , 2013, The Cochrane database of systematic reviews.

[2]  H. Diener,et al.  Influence of Age on Outcome From Thrombolysis in Acute Stroke: A Controlled Comparison in Patients From the Virtual International Stroke Trials Archive (VISTA) , 2010, Stroke.

[3]  M. Kaste,et al.  Comparison of Outcomes Following Thrombolytic Therapy Among Patients With Prior Stroke and Diabetes in the Virtual International Stroke Trials Archive (VISTA) , 2010, Diabetes Care.

[4]  L. Svensson,et al.  Intra-Arrest Transnasal Evaporative Cooling: A Randomized, Prehospital, Multicenter Study (PRINCE Pre-ROSC IntraNasal Cooling Effectiveness) , 2010, Circulation.

[5]  M. Kaste,et al.  Off-Label Thrombolysis Is Not Associated With Poor Outcome in Patients With Stroke , 2010, Stroke.

[6]  Ann P Rafferty,et al.  Lack of Association Between Stroke Symptom Knowledge and Intent to Call 911: A Population-Based Survey , 2010, Stroke.

[7]  Rema Raman,et al.  Stroke Team Remote Evaluation Using a Digital Observation Camera in Arizona: The Initial Mayo Clinic Experience Trial , 2010, Stroke.

[8]  K. Furie,et al.  Conscious Sedation Versus General Anesthesia During Endovascular Therapy for Acute Anterior Circulation Stroke: Preliminary Results From a Retrospective, Multicenter Study , 2011 .

[9]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[10]  L. Goldstein,et al.  Hospital Arrival Time and Intravenous t-PA Use in US Academic Medical Centers, 2001–2004 , 2009, Stroke.

[11]  Wade S. Smith,et al.  Predictors of Good Clinical Outcomes, Mortality, and Successful Revascularization in Patients With Acute Ischemic Stroke Undergoing Thrombectomy: Pooled Analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI Trials , 2009, Stroke.

[12]  J. Broderick,et al.  Good clinical outcome after ischemic stroke with successful revascularization is time-dependent , 2009, Neurology.

[13]  Jeffrey L Saver,et al.  Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. , 2009, Stroke.

[14]  Penumbra Pivotal Stroke Trial Investigators The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease , 2009, Stroke.

[15]  Marc Fisher,et al.  Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations , 2009, Stroke.

[16]  Q. Shah,et al.  Super-Selective Intra-arterial Magnesium Sulfate in Combination With Nicardipine for the Treatment of Cerebral Vasospasm in Patients With Subarachnoid Hemorrhage , 2009, Neurocritical care.

[17]  A. Gunn,et al.  Does Head Cooling With Mild Systemic Hypothermia Affect Requirement for Blood Pressure Support? , 2009, Pediatrics.

[18]  L. Steinman,et al.  Systems biology and its application to the understanding of neurological diseases , 2009, Annals of neurology.

[19]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[20]  M. Luby,et al.  Acute Stroke Imaging Research Roadmap II , 2008, Stroke.

[21]  Geoffrey A. Donnan,et al.  Acute Stroke Imaging Research Roadmap , 2008, Stroke.

[22]  Joseph P Broderick,et al.  National US Estimates of Recombinant Tissue Plasminogen Activator Use: ICD-9 Codes Substantially Underestimate , 2008, Stroke.

[23]  G. Steinberg,et al.  Limb remote-preconditioning protects against focal ischemia in rats and contradicts the dogma of therapeutic time windows for preconditioning , 2008, Neuroscience.

[24]  Adnan I. Qureshi,et al.  Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .

[25]  S. Warach,et al.  Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. , 2007, Stroke.

[26]  J. Broderick,et al.  Intracranial Hemorrhage Associated With Revascularization Therapies , 2007, Stroke.

[27]  R. Sacco,et al.  Quality improvement in acute stroke , 2006, Neurology.

[28]  Eric E. Smith,et al.  Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke , 2005, Stroke.

[29]  Jane C Khoury,et al.  Revascularization End Points in Stroke Interventional Trials: Recanalization Versus Reperfusion in IMS-I , 2005, Stroke.

[30]  H. Lutsep,et al.  Safety and Efficacy of Mechanical Embolectomy in Acute Ischemic Stroke: Results of the MERCI Trial , 2005, Stroke.

[31]  Jeffrey L. Saver,et al.  Prehospital Neuroprotective Therapy for Acute Stroke: Results of the Field Administration of Stroke Therapy–Magnesium (FAST–MAG) Pilot Trial , 2004, Stroke.

[32]  J. Alger,et al.  Beyond Mismatch: Evolving Paradigms in Imaging the Ischemic Penumbra With Multimodal Magnetic Resonance Imaging , 2003, Stroke.

[33]  E. Kanal,et al.  The Cortical Ischemic Core and Not the Consistently Present Penumbra Is a Determinant of Clinical Outcome in Acute Middle Cerebral Artery Occlusion , 2003, Stroke.

[34]  U. Dirnagl,et al.  Stroke-induced Immunodeficiency Promotes Spontaneous Bacterial Infections and Is Mediated by Sympathetic Activation Reversal by Poststroke T Helper Cell Type 1–like Immunostimulation , 2003, The Journal of experimental medicine.

[35]  H. Diener,et al.  European Stroke Initiative Recommendations for Stroke Management – Update 2003 , 2003, Cerebrovascular Diseases.

[36]  Alan D. Lopez,et al.  Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. , 2002, The New England journal of medicine.

[37]  Michael Holzer,et al.  Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest , 2002 .

[38]  A. Demchuk,et al.  Why are stroke patients excluded from TPA therapy? , 2001, Neurology.

[39]  G. Hankey,et al.  European Stroke Initiative Recommendations for Stroke Management , 2000, Cerebrovascular Diseases.

[40]  P. Akins,et al.  Intra-arterial prourokinase for acute ischemic stroke. , 2000, JAMA.

[41]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[42]  M. Moskowitz,et al.  Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.

[43]  H. Ellis stroke , 1997, The Lancet.

[44]  V Larrue,et al.  Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. , 1997, Stroke.

[45]  P. Duncan,et al.  Health status of individuals with mild stroke. , 1997, Stroke.

[46]  A. Furlan Clot retrieval for stroke should be restricted to clinical trials: no. , 2010, Stroke.